Combined Effects of Glucocorticoid and Noradrenergic Activity on Loss Aversion

Zsofia Margittai*, Gideon Nave, Marijn Van Wingerden, Alfons Schnitzler, Lars Schwabe, Tobias Kalenscher

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Loss aversion is a well-known behavioral regularity in financial decision making, describing humans' tendency to overweigh losses compared to gains of the same amount. Recent research indicates that stress and associated hormonal changes affect loss aversion, yet the underlying neuroendocrine mechanisms are still poorly understood. Here, we investigated the causal influence of two major stress neuromodulators, cortisol and noradrenaline, on loss aversion during financial decision making. In a double-blind, placebo-controlled between-subject design, we orally administered either the α2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy young men. We tested the treatments' influence on a financial decision-making task measuring loss aversion and risk attitude. We found that both drugs combined, relative to either drug by itself, reduced loss aversion in the absence of an effect on risk attitude or choice consistency. Our data suggest that concurrent glucocorticoid and noradrenergic activity prompts an alignment of reward- with loss-sensitivity, and thus diminishes loss aversion. Our results have implications for the understanding of the susceptibility to biases in decision making.
Original languageEnglish
Pages (from-to)334-341
Number of pages8
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Volume43
Issue number2
DOIs
Publication statusPublished - 1 Jan 2018
Externally publishedYes

Fingerprint

Glucocorticoids
Placebos
Adrenergic Antagonists
Pharmaceutical Preparations
Neurotransmitter Agents

Cite this

Margittai, Zsofia ; Nave, Gideon ; Van Wingerden, Marijn ; Schnitzler, Alfons ; Schwabe, Lars ; Kalenscher, Tobias. / Combined Effects of Glucocorticoid and Noradrenergic Activity on Loss Aversion. In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2018 ; Vol. 43, No. 2. pp. 334-341.
@article{8a3748e9eea04bb3859da95a45f42588,
title = "Combined Effects of Glucocorticoid and Noradrenergic Activity on Loss Aversion",
abstract = "Loss aversion is a well-known behavioral regularity in financial decision making, describing humans' tendency to overweigh losses compared to gains of the same amount. Recent research indicates that stress and associated hormonal changes affect loss aversion, yet the underlying neuroendocrine mechanisms are still poorly understood. Here, we investigated the causal influence of two major stress neuromodulators, cortisol and noradrenaline, on loss aversion during financial decision making. In a double-blind, placebo-controlled between-subject design, we orally administered either the α2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy young men. We tested the treatments' influence on a financial decision-making task measuring loss aversion and risk attitude. We found that both drugs combined, relative to either drug by itself, reduced loss aversion in the absence of an effect on risk attitude or choice consistency. Our data suggest that concurrent glucocorticoid and noradrenergic activity prompts an alignment of reward- with loss-sensitivity, and thus diminishes loss aversion. Our results have implications for the understanding of the susceptibility to biases in decision making.",
author = "Zsofia Margittai and Gideon Nave and {Van Wingerden}, Marijn and Alfons Schnitzler and Lars Schwabe and Tobias Kalenscher",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/npp.2017.75",
language = "English",
volume = "43",
pages = "334--341",
journal = "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
issn = "1740-634X",
number = "2",

}

Combined Effects of Glucocorticoid and Noradrenergic Activity on Loss Aversion. / Margittai, Zsofia; Nave, Gideon; Van Wingerden, Marijn; Schnitzler, Alfons; Schwabe, Lars; Kalenscher, Tobias.

In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Vol. 43, No. 2, 01.01.2018, p. 334-341.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Combined Effects of Glucocorticoid and Noradrenergic Activity on Loss Aversion

AU - Margittai, Zsofia

AU - Nave, Gideon

AU - Van Wingerden, Marijn

AU - Schnitzler, Alfons

AU - Schwabe, Lars

AU - Kalenscher, Tobias

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Loss aversion is a well-known behavioral regularity in financial decision making, describing humans' tendency to overweigh losses compared to gains of the same amount. Recent research indicates that stress and associated hormonal changes affect loss aversion, yet the underlying neuroendocrine mechanisms are still poorly understood. Here, we investigated the causal influence of two major stress neuromodulators, cortisol and noradrenaline, on loss aversion during financial decision making. In a double-blind, placebo-controlled between-subject design, we orally administered either the α2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy young men. We tested the treatments' influence on a financial decision-making task measuring loss aversion and risk attitude. We found that both drugs combined, relative to either drug by itself, reduced loss aversion in the absence of an effect on risk attitude or choice consistency. Our data suggest that concurrent glucocorticoid and noradrenergic activity prompts an alignment of reward- with loss-sensitivity, and thus diminishes loss aversion. Our results have implications for the understanding of the susceptibility to biases in decision making.

AB - Loss aversion is a well-known behavioral regularity in financial decision making, describing humans' tendency to overweigh losses compared to gains of the same amount. Recent research indicates that stress and associated hormonal changes affect loss aversion, yet the underlying neuroendocrine mechanisms are still poorly understood. Here, we investigated the causal influence of two major stress neuromodulators, cortisol and noradrenaline, on loss aversion during financial decision making. In a double-blind, placebo-controlled between-subject design, we orally administered either the α2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydrocortisone, both substances, or a placebo to healthy young men. We tested the treatments' influence on a financial decision-making task measuring loss aversion and risk attitude. We found that both drugs combined, relative to either drug by itself, reduced loss aversion in the absence of an effect on risk attitude or choice consistency. Our data suggest that concurrent glucocorticoid and noradrenergic activity prompts an alignment of reward- with loss-sensitivity, and thus diminishes loss aversion. Our results have implications for the understanding of the susceptibility to biases in decision making.

UR - http://www.mendeley.com/research/combined-effects-glucocorticoid-noradrenergic-activity-loss-aversion

U2 - 10.1038/npp.2017.75

DO - 10.1038/npp.2017.75

M3 - Article

VL - 43

SP - 334

EP - 341

JO - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

SN - 1740-634X

IS - 2

ER -